

Frontier Pharmacy: Demand, Sales, Competitor and Forecast 2016 – 2021

Frontier Pharmacy Global Market 2016 Prospectus, Examination and Forecast to 2021

PUNE, INDIA, October 13, 2016

/EINPresswire.com/ -- Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. In the US and EU, the annual incidence

was estimated to be three to four cases per 100,000 people. GBM has a high degree of intratumoral heterogeneity, which is associated with poor prognosis and the development of drug resistance.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/659875-frontier-pharma-glioblastoma-multiforme-class-product-innovation>

The GBM market is characterized by a small selection of marketed product options, consisting of chemotherapies, cancer immunotherapies and receptor tyrosine kinase inhibitor products. The pipeline is moderately large, with 512 products active across all stages of development. First-in-class products only constitute approximately a quarter of the pipeline, and represent 31% of products with a disclosed target. The most widely studied group of first-in-class targets are the receptor tyrosine kinase and ligand inhibitors, a trend that has been heavily influenced by the success of Avastin, and possibly successful EGFR inhibitors such as Tarceva that are used in the treatment of other oncology indications.

Potential driving factors for the market include a typically poor outcome for treated patients, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market, and a strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fulfill the unmet needs.

Overall, due to the highly complex and polygenic nature of GBM, which has numerous subtype classifications, it is unlikely that the inhibition of a single target will be sufficient to substantially improve patient prognosis. Instead, it is more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, may improve treatment outcomes. First-in-class targets analyzed in this report have shown encouraging efficacy profiles, and some show the ability to chemosensitize cancer cells.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Scope

- The report analyzes innovation in GBM, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products, and pinpoints opportunities for in-licensing.
- A brief introduction to GBM, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, including particular focal points of innovation in the pipeline.
- A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for GBM therapies.

Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options.
- Visualize the composition of the GBM market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the GBM pipeline, stratified by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the GBM deals landscape by analyzing trends in licensing and co-development deals.

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=659875

Table of Content

1	Table of Contents	2
1.1	List of Tables	3
1.2	List of Figures	3
2	Executive Summary	4
2.1	Low Prevalence but a High Unmet Need and a Limited Number of Marketed Options	4
2.2	Moderately Sized but Innovative Pipeline	4
2.3	Moderately Active Deals Landscape, Mostly Involving Currently Established Targets	4
3	The Case for Innovation in the Glioblastoma Multiforme Market	5
3.1	Growing Opportunities for Biologic Products	5
3.2	Diversification of Molecular Targets	6
3.3	Innovative First-in-Class Product Developments Remain Attractive	6
3.4	Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications	6
3.5	Sustained Innovation	7
3.6	Report Guidance	7
4	Clinical and Commercial Landscape	8
4.1	Disease Overview	8
4.2	Epidemiology	8
4.3	Disease Symptoms	8

- 4.4 Etiology 9
- 4.5 Pathophysiology 11
- 4.6 Diagnosis 14
- 4.7 GBM Prognosis and Prognostic Factors 15
- 4.8 Classification 15
- 5 Assessment of Pipeline Product Innovation 24
 - 5.1 Glioblastoma Pipeline by Phase, Molecule Type and Molecular Target 24
 - 5.2 First-in-Class Pipeline Programs 28
- 6 Signaling Network, Disease Causation and Innovation Alignment 33
 - 6.1 The Complexity of Signaling Networks in Oncology 33
 - 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 34
 - 6.3 First-in-Class Target Matrix Assessment 34
- 7 First-in-Class Target Evaluation 36
 - 7.1 Pipeline Programs Targeting AKT 1 and 2 36
 - 7.2 Pipeline Programs Targeting CDK1/2 37
 - 7.3 Pipeline Programs Targeting PIK3CB and PIK3CG 38
 - 7.4 Pipeline Programs which Target NTRK1 39
- 8 Deals and Strategic Consolidations 48
 - 8.1 Industry-Wide First-in-Class Deals 48
 - 8.2 Glioblastoma Multiforme Deals Landscape 49
 - 8.3 Licensing Deals 50
- 9 Appendix 59
 - 9.1 Abbreviations 59
 - 9.2 References 60
 - 9.6 Disclaimer 73

Access Report @ <https://www.wiseguyreports.com/reports/638808-frontier-pharma-chronic-acute-to-treat-subtypes>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.